
Current treatments of zzso multiple sclerosis zzso with zzso or zzso drugs have been shown to modify the course of the disease in a zzso number of zzso However, in many cases, the response to either zzso beta zzso or zzso zzso treatments was not satisfactory and new therapeutic approaches are zzso We studied clinical and zzso zzso safety and tolerance of zzso and zzso combined therapy in 23 patients with clinically zzso zzso who had not previously been responsive to either zzso Our cases were divided into three zzso 8 previously zzso patients zzso zzso with at least 2 years of natural course of the disease, 8 patients zzso zzso previously treated with zzso for 2 years and 7 patients zzso zzso previously treated with zzso for 2 zzso The baseline Expanded zzso zzso zzso zzso ranged from 2 to 4 in all zzso All patients completed 2 years of combined treatment with a dose of zzso adjusted to reduce zzso count down to 1,000 zzso zzso in association with zzso at a dose of 6 zzso every other zzso The mean number of relapses during the combined treatment period was significantly lower than that observed before combined therapy in all the three zzso Also, the mean Delta zzso score was significantly lower during combined treatment than in zzso in zzso B and zzso Moreover, after 2 years of combined treatment, the number of new zzso zzso zzso the number and volume of zzso zzso zzso zzso and the zzso enhancement of zzso zzso zzso were significantly lower than before combined zzso After 2 years of treatment, this combination therapy appears to be safe and well tolerated and no serious side effects were zzso Despite some limitations of our study design, the information regarding zzso safety and tolerance of the association of zzso and zzso is most zzso 

